Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946799 | 0.81 | LMNA (0.43) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL5185398 | 0.81 | SRC (0.45) | LMNAAPPKDM4EMAPTGRM1 | |
| SCHEMBL5706839 | 0.81 | CYP17A1 (0.44) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL591501 | 0.77 | ALDH1A1 (0.45) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL2533923 | 0.77 | KCNH2 (0.46) | LMNAKDM4EHTR1AADRA1DADRA1A | |
| SCHEMBL2535928 | 0.77 | KCNH2 (0.43) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL5813519 | 0.77 | KCNH2 (0.43) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL2954867 | 0.77 | KDM4E (0.42) | LMNAKDM4EMAPTGRM1GABRA1 | |
| SCHEMBL6279199 | 0.76 | KCNH2 (0.45) | LMNAKDM4EMAPK1NPSR1 | |
| SCHEMBL6270490 | 0.76 | KDM4E (0.50) | LMNAKDM4EMAPTGABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1695964-A1 | Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines | NOVEXEL (FR) | 2006-08-30 | — | — | EP | claimed |
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | claimed |
| US-7348434-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | BIGOT ANTONY | 2008-03-25 | — | — | US | disclosed |
| US-20080032985-A1 | 4-Substituted Quinoline Derivatives, Method and Intermediates for Their Preparation and Pharmaceutical Compositions Containing Them | NOVEXEL (FR) | 2008-02-07 | — | — | US | disclosed |
| CN-101023076-A | 4-substituted quinoline derivatives, method and intermediates for preparing same and pharmaceutical compositions containing same | NOVEXEL (FR) | 2007-08-22 | — | — | CN | disclosed |
| US-7232833-B2 | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them | NOVEXEL (FR) | 2007-06-19 | — | — | US | disclosed |
| US-7232834-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL SA (FR) | 2007-06-19 | — | — | US | disclosed |
| EP-1370550-B1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2007-05-23 | — | — | EP | disclosed |
| EP-1763527-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES, METHOD AND INTERMEDIATES FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | NOVEXEL (FR) | 2007-03-21 | — | — | EP | disclosed |
| EP-1695964-A1 | Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines | NOVEXEL (FR) | 2006-08-30 | — | — | EP | disclosed |
| EP-1695964-A1 | Quinoline derivatives for use as intermediates in the synthesis of heterocyclylalcoyl piperidines | NOVEXEL (FR) | 2006-08-30 | — | — | EP | disclosed |
| EP-1370550-A1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-12-17 | — | — | EP | disclosed |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | AVENTIS PHARMA S.A. | 2003-09-11 | — | — | US | disclosed |
| EP-1337529-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 2003-08-27 | — | — | EP | disclosed |
| US-6603005-B2 | Bactericides | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-6602884-B2 | Useful as antibiotics against Staphylococcus, Streptococcus, Enterococcus and Moraxella | AVENTIS PHARMA S.A. (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | NOVEXEL (FR) | 2002-11-28 | — | — | US | disclosed |
| WO-2002072572-A1 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2002-09-19 | — | — | WO | disclosed |
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | NOVEXEL (FR) | 2002-08-15 | — | — | US | disclosed |
| WO-2002040474-A2 | HETEROCYCLYLALKYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111492-A1 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | SYNJ1, NCAPD2, SYNJ2 | LMNA 295/4885APP 917/4885KDM4E 4252/4885 |
| US-20020177606-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | LMNA 3014/4885APP 3093/4885KDM4E 2771/4885 |
| US-20080032985-A1 | 4-Substituted Quinoline Derivatives, Method and Intermediates for Their Preparation and Pharmaceutical Compositions Containing Them | CYP3A7, CYP3A4, CYP4B1 | LMNA 2305/4885APP 2303/4885KDM4E 1252/4885 |
| US-20030171369-A1 | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them | QDPR, MRPL21, RPLP2 | LMNA 3014/4885APP 3093/4885KDM4E 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.